A phase II study of irinotecan and docetaxel combination chemotherapy for patients with previously treated metastatic or recurrent advanced gastric cancer

Cancer Chemotherapy and Pharmacology

Volumn 63, Issue 1, 2008, Pages 1-8

  Sym, Sun Jin ^a   Chang, Heung Moon ^a   Kang, Hye Jin ^b   Lee, Sung Sook ^a   Ryu, Min Hee ^a   Lee, Jae Lyun ^a   Kim, Tae Won ^a   Yook, Jeong Hwan ^a   Oh, Sung Tae ^a   Kim, Byung Sik ^a   Kang, Yoon Koo ^a  

^a University of Ulsan College of Medicine   (South Korea)

^b Korea Institute of Radiation and Medical Science   (South Korea)

Author keywords

Chemotherapy; Docetaxel; Gastric cancer; Irinotecan

Indexed keywords

ATROPINE; DEXAMETHASONE; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; FLUOROPYRIMIDINE; FLUOROURACIL; IRINOTECAN; LOPERAMIDE; METHOTREXATE; PHENIRAMINE MALEATE; PLATINUM DERIVATIVE;

ADULT; ADVANCED CANCER; AGED; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTICLE; ASTHENIA; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; EDEMA; FEBRILE NEUTROPENIA; FEMALE; HEMATOLOGIC DISEASE; HUMAN; LEUKOPENIA; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; STOMACH CANCER; STOMATITIS; THROMBOCYTOPENIA; TREATMENT FAILURE; VOMITING;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASTHENIA; CAMPTOTHECIN; DISEASE PROGRESSION; FEMALE; GASTROINTESTINAL DISEASES; HEMATOLOGIC DISEASES; HUMANS; MALE; MIDDLE AGED; REMISSION INDUCTION; STOMACH NEOPLASMS; SURVIVAL ANALYSIS; TAXOIDS;

EID: 39149107799     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-008-0701-2     Document Type: Article

References (32)

1. DM Parkin F Bray J Ferlay P Pisani 2005 Global cancer statistics, 2002 CA Cancer J Clin 55 74 108
2. HR Shin KW Jung YJ Won JG Park 2004 2002 annual report of the Korea central cancer registry: based on registered data from 139 hospitals Cancer Res Treat 36 103 114
3. B Glimelius K Hoffman U Haglund O Nyren PO Sjoden 1994 Initial or delayed chemotherapy with best supportive care in advanced gastric cancer Ann Oncol 5 189 190
4. AM Murad FF Santiago A Petroianu PR Rocha MA Rodrigues M Rausch 1993 Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer Cancer 72 37 41
5. S Pyrhonen T Kuitunen P Nyandoto M Kouri 1995 Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer Br J Cancer 71 587 591
6. NK Kim YS Park DS Heo C Suh SY Kim KC Park YK Kang DB Shin HT Kim HJ Kim 1993 A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer Cancer 71 3813 3818
7. A Ohtsu Y Shimada K Shirao N Boku I Hyodo H Saito N Yamamichi Y Miyata N Ikeda S Yamamoto H Fukuda S Yoshida 2003 Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205) J Clin Oncol 21 54 59
8. JS Waters A Norman D Cunningham JH Scarffe A Webb P Harper JK Joffe M Mackean J Mansi M Leahy A Hill J Oates S Rao M Nicolson T Hickish 1999 Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial Br J Cancer 80 269 272
9. TW Kim YK Kang JH Ahn HM Chang JH Yook ST Oh BS Kim JS Lee 2002 Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced gastric cancer Ann Oncol 13 1893 1898
10. W Koizumi S Tanabe K Saigenji A Ohtsu N Boku F Nagashima K Shirao Y Matsumura M Gotoh 2003 Phase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancer Br J Cancer 89 2207 2212
11. K Sumpter C Harper-Wynne D Cunningham S Rao N Tebbutt AR Norman C Ward T Iveson M Nicolson T Hickish M Hill J Oates 2005 Report of two protocol planned interim analyses in a randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer receiving ECF Br J Cancer 92 1976 1983
12. Y Kang WK Kang DB Shin J Chen J Xiong J Wang M Lichinitser MP Salas T Suarez J Santamaria 2006 Randomized phase III trial of capecitiabine/cisplatin (XP) vs. continuous infusion of 5-FU/cisplatin (FP) as first-line therapy in patients with advanced gastric cancer (AGC): efficacy and safety results Proc Am Soc Clin Oncol 24 183S
13. F Gueritte-Voegelein D Guenard F Lavelle MT Le Goff L Mangatal P Potier 1991 Relationships between the structure of taxol analogues and their antimitotic activity J Med Chem 34 992 998
14. I Ringel SB Horwitz 1991 Studies with RP 56976 (taxotere): a semisynthetic analogue of taxol J Natl Cancer Inst 83 288 291
15. A Sulkes J Smyth C Sessa LY Dirix JB Vermorken S Kaye J Wanders H Franklin N LeBail J Verweij 1994 Docetaxel (Taxotere) in advanced gastric cancer: results of a phase II clinical trial. EORTC early clinical trials group Br J Cancer 70 380 383
16. AI Einzig D Neuberg SC Remick DD Karp PJ O'Dwyer JA Stewart AB Benson 3rd 1996 Phase II trial of docetaxel (Taxotere) in patients with adenocarcinoma of the upper gastrointestinal tract previously untreated with cytotoxic chemotherapy: the eastern cooperative oncology group (ECOG) results of protocol E1293 Med Oncol 13 87 93
17. U Vanhoefer H Wilke A Harstrick W Achterrath P Preusser M Stahl M Clemens E Thiel M Flasshove U Fink G Trenn S Seeber 1999 Phase II study of docetaxel as second line chemotherapy in metastatic gastric cancer Proc Am Soc Clin Oncol 18 303
18. F Giuliani V Gebbia F De Vita E Maiello M Di Bisceglie G Catalano N Gebbia G Colucci 2003 Docetaxel as salvage therapy in advanced gastric cancer: a phase II study of the Gruppo Oncologico Italia Meridionale (G.O.I.M.) Anticancer Res 23 4219 4222
19. JL Lee MH Ryu HM Chang TW Kim JH Yook ST Oh BS Kim M Kim YJ Chun JS Lee YK Kang 2008 A phase II study of docetaxel as salvage chemotherapy in advanced gastric cancer after failure of fluoropyrimidine and platinum combination chemotherapy. Cancer Chemother Pharmacol 61 4 631 637
20. A Tanizawa A Fujimori Y Fujimori Y Pommier 1994 Comparison of topoisomerase I inhibition, DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials J Natl Cancer Inst 86 836 842
21. JH Chun HK Kim JS Lee JY Choi HG Lee SM Yoon IJ Choi KW Ryu YW Kim JM Bae 2004 Weekly irinotecan in patients with metastatic gastric cancer failing cisplatin-based chemotherapy Jpn J Clin Oncol 34 8 13
22. K Futatsuki A Wakui I Nakao Y Sakata M Kambe Y Shimada M Yoshino T Taguchi N Ogawa 1994 [Late phase II study of irinotecan hydrochloride (CPT-11) in advanced gastric cancer. CPT-11 Gastrointestinal Cancer Study Group] Gan To Kagaku Ryoho 21 1033 1038
23. K Okishio S Kudoh K Hirata 1995 Schedule dependent additive effect of docetaxel and irinotecan in vitro Proc Jpn J Cancer Res 86 619
24. AA Adjei CE Klein H Kastrissios RM Goldberg SR Alberts HC Pitot JA Sloan JM Reid LJ Hanson P Atherton J Rubin C Erlichman 2000 Phase I and pharmacokinetic study of irinotecan and docetaxel in patients with advanced solid tumors: preliminary evidence of clinical activity J Clin Oncol 18 1116 1123
25. A Jatoi MT Tirona SS Cha SR Alberts KM Rowland RF Morton S Nair CG Kardinal PJ Stella JA Mailliard D Sargen RM Goldberg 2002 A phase II trial of docetaxel and CPT-11 in patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction, and gastric cardia Int J Gastrointest Cancer 32 115 123
26. F Lordick C von Schilling H Bernhard M Hennig R Bredenkamp C Peschel 2003 Phase II trial of irinotecan plus docetaxel in cisplatin-pretreated relapsed or refractory oesophageal cancer Br J Cancer 89 630 633
27. C Couteau ML Risse M Ducreux F Lefresne-Soulas A Riva A Lebecq P Ruffie P Rougier F Lokiec R Bruno JP Armand 2000 Phase I and pharmacokinetic study of docetaxel and irinotecan in patients with advanced solid tumors J Clin Oncol 18 3545 3552
28. R Hawkins D Cunningham H Soerbye A Adenis J-L Canon G Lopez-Vicanco C Jacques P Stenger E Zuber J-L Misset 2003 Randomized phase II trial of docetaxel plus irinotecan versus docetaxel plus 5-fluorouracil (5FU) in patients with untreated advanced gastric adenocarcinoma (AGAC). Proc Am Soc Clin Oncol 22 257
29. F Innocenti SD Undevia L Iyer PX Chen S Das M Kocherginsky T Karrison L Janisch J Ramirez CM Rudin EE Vokes MJ Ratain 2004 Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan J Clin Oncol 22 1382 1388
30. JE Kurtz S Negrier F Husseini JM Limacher C Borel JP Wagner G Prevot JP Bergerat P Dufour 2003 A phase II study of docetaxel-irinotecan combination in advanced pancreatic cancer Hepatogastroenterology 50 567 570
31. A Polyzos C Kosmas H Toufexi N Malamos A Lagadas C Kosmidis P Ginopoulos N Ziras K Kandilis V Georgoulias 2005 Docetaxel in combination with irinotecan (CPT-11) in platinum-resistant paclitaxel-pretreated ovarian cancer Anticancer Res 25 3559 3564
32. SR Park JH Chun MS Yu JH Lee KW Ryu IJ Choi CG Kim JS Lee YW Kim JM Bae HK Kim 2006 Phase II study of docetaxel and irinotecan combination chemotherapy in metastatic gastric carcinoma Br J Cancer 94 1402 1406